Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.
about
Biology of parainfluenza virusesPathogenesis of acute respiratory illness caused by human parainfluenza virusesReplacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidatesRecovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.Antiviral activity of ginseng extract against respiratory syncytial virus infectionRecombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.Immunization of pediatric solid organ transplant candidates and recipients.Progress in the development of human parainfluenza virus vaccinesMucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backboneThe C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger activation of MDA5 and protein kinase RAlix serves as an adaptor that allows human parainfluenza virus type 1 to interact with the host cell ESCRT systemAttenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.Viral and host factors in human respiratory syncytial virus pathogenesis.Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium.Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: use of reverse transcription-PCR-enzyme immunoassay.The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infectionRegulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparitiesEvaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.The challenges in developing effective canine infectious respiratory disease vaccines.Respiratory syncytial virus: a systematic scientometric analysis of the global publication output and the gender distribution of publishing authorsCharge-to-alanine mutagenesis of the adeno-associated virus type 2 Rep78/68 proteins yields temperature-sensitive and magnesium-dependent variants.Rapid diagnosis of human parainfluenza virus type 1 infection by quantitative reverse transcription-PCR-enzyme hybridization assay.Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.Parainfluenza type 1 virus-infected cells are killed by both CD8+ and CD4+ cytotoxic T cell precursors.Identification of a natural human serotype 3 parainfluenza virus.Selection and characterization of human respiratory syncytial virus escape mutants resistant to a polyclonal antiserum raised against the F protein.Combination live respiratory virus vaccines.
P2860
Q24615805-5710F347-B918-4623-8EF7-CF37C123B48FQ27000151-04609AF5-9E70-41E7-A6D2-061BF3893196Q27469676-5FBD01FA-0926-4DFF-B7C2-FA3703595A95Q33783083-700849C4-5B45-41C9-82F6-F7F9050DB404Q33811236-BE006827-AD17-47B6-B01F-B51DBB3B844DQ33840469-FC12E013-281A-4B8B-9B0F-B81524C51260Q33942411-89C62F0B-5C08-4B09-A8D9-AF2A6F0E9F77Q34209872-4F70E227-424A-40D8-9D56-A5AB3B7CB318Q34328895-02F48F57-3869-44E0-898D-7894E75A9541Q34529862-7CCAB219-64AA-4F41-9177-A4D8BC4D37ADQ34635209-637D9D70-5B1B-44A4-A7DA-7938A48F4B9FQ35924915-446AD1ED-367B-4C40-B689-2403C2BBA1C7Q36483836-0ACB2BF7-99B4-4DF6-826D-BB4C85C4385AQ36845674-0F316C75-7B91-4431-AE41-D4D0FD031009Q36898701-CC619BB9-3979-4742-A111-F269D772FC92Q37071979-CAA917D1-CC93-448B-9DB6-500E5D3C70EEQ37099848-836F8BE9-C283-4553-BB21-26505F2080D3Q37127882-47630BD4-4A10-475D-8DE9-3C935B2DB9C6Q37235698-548D18BB-0A48-4461-B3BE-26DD5F1634E0Q37347267-B5A3745F-6C70-47E2-BA8B-DE97D7A598A1Q37468212-18D68EA5-C66C-4FA0-B0C3-CDC1F553CFC5Q37713874-5F530D2F-D20C-4BCA-A2DF-D1D8A730F209Q38367399-DF6BD594-1409-488E-8BD7-0CBC48E2D65BQ38656562-AEA248B8-B243-4495-9F97-4B25337380FFQ39596582-50FC562C-682E-49DC-80D0-4CE72026929AQ40011280-BD8F5FCE-70D3-4270-BF5F-2380D4DFFA6DQ40187606-2FCAF5B0-ECF0-4FCB-AC76-91F7C3C41422Q41528992-74C46D03-BF15-4B8F-93B1-BF8D7CE1FF4BQ41907672-632B644E-4BD3-4FC5-8EF5-AA65B09FC395Q45359023-F449B475-ABC0-44A6-86D4-9C8AB1A9C6BDQ45787801-F85CC7A8-928D-4830-8049-D893E8C8539E
P2860
Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Current approaches to the deve ...... respiratory syncytial viruses.
@en
Current approaches to the deve ...... respiratory syncytial viruses.
@nl
type
label
Current approaches to the deve ...... respiratory syncytial viruses.
@en
Current approaches to the deve ...... respiratory syncytial viruses.
@nl
prefLabel
Current approaches to the deve ...... respiratory syncytial viruses.
@en
Current approaches to the deve ...... respiratory syncytial viruses.
@nl
P2093
P1433
P1476
Current approaches to the deve ...... respiratory syncytial viruses.
@en
P2093
Chanock RM
Collins PL
Olmsted RA
Parrott RH
Spriggs MK
Van Wyke Coelingh K
P356
10.1016/0168-1702(88)90063-9
P577
1988-08-01T00:00:00Z